Clinical trials: Schizophrenia Disorders
Schizophrenia
A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®
To compare inpatient psychiatric hospitalization rates while participants are on oral standard-of-care antipsychotic treatment and later switched to Abilify MyCite®.
- Trial name
- NCT03892889
- Testing
- Abilify MyCite®
- Where
- 68 sites in United States
- Volunteers
- 277 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)
This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning.
- Trial name
- NCT04846868
- Testing
- Iclepertin
- Where
- 116 sites in United States, Australia and 15 more
- Volunteers
- 620 people
- Sponsor
- Boehringer Ingelheim
Psychosis
USS Training to Improve Social Function in People With Psychosis
Psychotic spectrum disorders (PSD) are associated with poor social function. By doing this study, the investigators hope to learn which of two different types of 2-month long training courses is more effective in improving…
- Trial name
- NCT04557124
- Testing
- USS, MovingForward
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- VA Office of Research and Development
Major Depression, Schizophrenia
Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness
Individuals with severe mental illness (SMI) including schizophrenia and bipolar disorder are dying younger than the general population; cancer is a leading cause of death in this population.
- Conditions
- Major Depression, Schizophrenia, Bipolar Disorder, Lung Cancer
- Trial name
- NCT02594696
- Testing
- Proactive Psychiatry Consultation (PPC)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Study of Efficacy and Safety of Seroquel (Quetiapine Fumarate) as Mono-Therapy for Acute Schizophrenic
The primary objective of the study is to evaluate the efficacy of quetiapine fumarate (Seroquel) with daily dose 600mg-750mg used as mono-therapy in the treatment of acute schizophrenic patients by evaluation of the change from…
- Trial name
- NCT00428350
- Testing
- Quetiapine Fumarate (Seroquel)
- Where
- 9 sites in China
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Psychosis
Mindfulness, Group Therapy and Psychosis; Training Decreases Anxiety and Depression
The objective of this non-randomized, within-group comparison was to evaluate the addition of mindfulness as a new technique in an outpatient group therapy program for participants diagnosed with a psychotic spectrum disorder…
- Trial name
- NCT04711460
- Testing
- Younger participants, Older participants, TAU
- Volunteers
- 116 people
- Sponsor
- University of Minnesota
Psychotic Disorders, Cannabis Use Disorder
RCT Comparing Avatar Intervention to Supportive Intervention to Reduce Cannabis Use in Patients With Psychotic Disorders
The goal of this clinical trial is to conduct a single-blind randomized controlled trial to verify whether the Avatar Intervention has greater efficacy over supportive intervention to reduce cannabis use in patients with…
- Conditions
- Psychotic Disorders, Cannabis Use Disorder, Mental Health Disorder
- Trial name
- AC2 (NCT05704582)
- Testing
- Avatar Intervention, Addiction supportive intervention
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Major Depression, Bipolar Disorder
Assessing the Impact of Self-directed Care, Within a Medicaid-funded Environment,on Participation and Community Living
This project proposed to demonstrate the effectiveness, costs, and benefits to participation and community living self-directed care programming within a financially sustainable Medicaid managed care environment.
- Conditions
- Major Depression, Bipolar Disorder, Schizophrenia
- Trial name
- NCT02520024
- Testing
- self-directed care
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Temple University Collaborative on Community Inclusion
Mental Disorder, Schizophrenia Diagnosis
Validation of a VOICE MAnagement Program in Schizophrenia VVoice MAPS
Approximately 25-50% of patients with schizophrenia experience treatment-resistant Auditory Verbal Hallucinations (AVHs), which contribute to the development of associated psychopathological disorders (e.g., anxiety, depression…
- Trial name
- PROGEVs (NCT07266376)
- Testing
- Integrative group therapy
- Where
- Guadeloupe
- Volunteers
- 116 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Schizophrenia
Exploratory Study of a Digital Therapeutics in People With Schizophrenia
CT-155 is a novel prescription digital therapeutic (PDT) being developed by Click Therapeutics, Inc. (Click) and Boehringer Ingelheim (BI) using an interactive, software-based intervention to treat schizophrenia
- Trial name
- NCT05438160
- Testing
- Clinical Learning Study smartphone app (i.e., the study app)
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Click Therapeutics, Inc.
Schizophrenia, Catatonia
Anatomical and Structural Connectivity in Two Psychotic Phenotypes : Periodic Catatonia and Cataphasia
The different subtypes of Schizophrenia might have a disordered connectivity as their final common pathways. The investigators will use multimodal structural MRI to assess anatomical connectivity on the one side and its…
- Trial name
- NCT02868879
- Testing
- Quantitative multiparametric and functional MRI
- Where
- France
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Schizophrenia
Neural Correlates of Social Touch and Interoceptive Perception As Potential Biomarker for Impaired Social Functioning
Recent studies have shown that certain biomarkers of schizophrenia could help to better assess the individual course of the disease and thus, contribute to more personalized treatment options.
- Trial name
- SPIRIT (NCT04968223)
- Where
- Germany
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- University of Oldenburg
Schizophrenia
Shiatsu Adjuvant Therapy For Schizophrenia
In the current study we will study the effect of adding shiatsu treatment to conventional therapy in work with hospitalized schizophrenic patients. The hypotheses of this study are several: 1.
- Trial name
- NCT00425399
- Testing
- Shiatsu
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Herzog Hospital
DiGeorge Syndrome, Velocardiofacial Syndrome
Velocardiofacial (VCFS; 22q11.2; DiGeorge) Syndrome Study
Velocardiofacial syndrome, also known as 22q11.2 syndrome or DiGeorge syndrome, has been associated with many features such as a cleft palate, heart defects, and learning, speech and feeding problems.
- Conditions
- DiGeorge Syndrome, Velocardiofacial Syndrome, 22q11.2 Syndrome
- Trial name
- NCT00105274
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia
A Study of the Effects of Paroxetine on the Pharmacokinetics of Paliperidone ER
The purpose of this study is to evaluate the effects of a CYP2D6 inhibitor, paroxetine, on the pharmacokinetics of a single dose of orally administered paliperidone ER and to evaluate the safety and tolerability of both…
- Trial name
- NCT00791713
- Testing
- Paliperidone ER
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia
The purpose of this study is to evaluate the pharmacokinetics (study of what the body does to a drug) and safety of paliperidone palmitate ranging from 75 to 150 milligram equivalents in repeated doses (4 injections) administered…
- Trial name
- NCT01942382
- Testing
- Paliperidone palmitate
- Volunteers
- 76 people
- Sponsor
- Janssen Pharmaceutical K.K.
Schizophrenia
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
This is an extension of a previous study (ALK9072-003EXT). The purpose of this study is to continue to evaluate the long-term safety and durability of effect of ALKS 9072 in subjects with stable schizophrenia, and to allow…
- Trial name
- NCT01895452
- Testing
- ALKS 9072, Low Dose, ALKS 9072, High Dose
- Where
- 57 sites in United States, Bulgaria and 6 more
- Volunteers
- 291 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
The Efficacy and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia
A clinical study to compare the safety and effectiveness of two different dose ranges of risperidone solution in the treatment of adolescents with a diagnosis of schizophrenia.
- Trial name
- NCT00034749
- Testing
- Risperidone
- Volunteers
- 279 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Autism Spectrum Disorder, Schizophrenia Disorder
Understanding and Treating Severe and Resistant Pathological Aggression: Using Deep Brain Stimulation to Treat Resistant Aggression
Physical aggression can be defined as the use of force with the intention of causing physical injury, psychological damage or death. Pathological aggression may be associated with various psychiatric disorders.
- Trial name
- STAR (NCT07315685)
- Testing
- neurostimulator
- Where
- 2 sites in France
- Volunteers
- 6 people
- Sponsor
- University Hospital, Rouen
Schizophrenia, Schizo Affective Disorder
Cognitive Training for Emotion Regulation in Psychotic Disorders
The current study examines the efficacy of a cognitive training intervention for improving emotion regulation in psychotic disorders.
- Trial name
- NCT04414215
- Testing
- Emotional working memory training
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Georgia